Citius Oncology, Inc.
CTORHealthcare|Medical - Pharmaceuticals|US
$0.51
+0.01 (+1.88%)
DCF Value
$0.10
Cash / Share
$0.15
Financials
Financial Snapshot
Market Cap
$47.4M
Enterprise Value
$41.0M
Revenue (TTM)
$7.1M
Net Income (TTM)
-$46.1M
Cash & Investments
$16.6M
Net Cash
$6.4M
Free Cash Flow (TTM)
-$19.7M
Operating CF (TTM)
-$19.7M
Debt/Equity
0.25
Cash Runway & Burn Rate
Cash on Hand
$16.6M
Quarterly Burn
$4.9M
Monthly Burn
$1.6M
Est. Runway
~3.4 quarters
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $0.00 | $112.00 | $3.9M | $16.6M | |
| Operating Cash Flow | -$48.0K | -$601.3K | $126.4K | -$5.5M | -$19.7M | |
| Free Cash Flow | -$48.0K | -$601.3K | $126.3K | -$5.5M | -$19.7M | |
| Capital Expenditure | $0.00 | $4.00 | -$4.00 | -$4.00 | -$14.00 | |
| Financing Cash Flow | $67.7M | $1.7M | $4.9M | $15.2M | $49.5M |
R&D Spending
R&D (TTM)
$3.4M
R&D Intensity
47.7%
R&D Growth vs Prior
-47.1%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $7.1M | |
| R&D Expense | $6.9M | $4.2M | $4.9M | $6.4M | $3.4M | |
| R&D % of Revenue | — | — | — | — | 47.7% | |
| SG&A | $2.9M | $7.9M | $15.6M | $17.1M | $45.4M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $7.1M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $3.3M | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $3.8M | |
| R&D | $6.9M | $4.2M | $4.9M | $6.4M | $3.4M | |
| SG&A | $2.9M | $7.9M | $15.6M | $17.1M | $45.4M | |
| Operating Income | -$9.7M | -$12.1M | -$20.6M | -$23.5M | -$47.3M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $218.0K | $547.4K | |
| Pretax Income | -$9.7M | -$12.1M | -$20.6M | -$23.7M | -$45.9M | |
| Net Income | -$10.9M | -$12.7M | -$21.1M | -$24.8M | -$46.1M | |
| EPS (Diluted) | -0.08 | -0.19 | -0.30 | -0.34 | -0.48 | |
| EBITDA | $0.00 | -$12.1M | -$20.6M | -$23.5M | -$43.1M | |
| Shares Out. (M) | 90.16 | 89.48 | 71.55 | 73.27 | 107.89 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $0.00 | $112.00 | $3.9M | $16.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.7M | $7.7M | $11.0M | $27.5M | $42.7M | |
| Total Assets | $42.7M | $47.7M | $84.4M | $100.9M | $112.1M | |
| Total Current Liabilities | $5.8M | $21.0M | $32.7M | $49.5M | $58.8M | |
| Long-Term Debt | $0.00 | $0.00 | $3.8M | $3.8M | $10.2M | |
| Total Liabilities | $6.4M | $22.2M | $38.2M | $56.1M | $71.7M | |
| Stockholders' Equity | $36.3M | $25.5M | $46.1M | $44.9M | $40.4M | |
| Retained Earnings | -$5.4M | -$18.1M | -$39.3M | -$64.0M | -$105.1M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$48.0K | -$601.3K | $126.4K | -$5.5M | -$19.7M | |
| Capital Expenditure | $0.00 | $4.00 | -$4.00 | -$4.00 | -$14.00 | |
| Free Cash Flow | -$48.0K | -$601.3K | $126.3K | -$5.5M | -$19.7M | |
| Investing Cash Flow | -$67.3M | -$1.3M | -$5.0M | -$5.8M | -$12.9M | |
| Financing Cash Flow | $67.7M | $1.7M | $4.9M | $15.2M | $49.5M | |
| Issuance of Stock | $68.0M | $0.00 | $0.00 | $15.2M | $39.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $3.8M | $0.00 | $9.8M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $289.2K | -$256.4K | -$32.6K | $3.9M | $16.6M |
Dilution Tracker
Shares Outstanding
93M
5-Year Share Growth
-18.7%
Stock Issuance (TTM)
$39.7M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 90.16 | 89.48 | 71.55 | 73.27 | 107.89 | |
| Change vs Prior % | — | -0.8% | -20.0% | 2.4% | 47.3% | |
| Stock Issuance | $68.0M | $0.00 | $0.00 | $15.2M | $39.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | 53.1% | |
| Operating Margin % | — | — | — | — | -665.6% | |
| Net Margin % | — | — | — | — | -648.3% | |
| EBITDA Margin % | — | — | — | — | -607.0% | |
| FCF Margin % | — | — | — | — | -277.3% | |
| ROE % | -30.0% | -49.7% | -45.8% | -55.2% | -103.0% | |
| ROA % | -25.5% | -26.6% | -25.1% | -24.5% | -41.1% | |
| ROIC % | -26.4% | -45.4% | -39.8% | -45.7% | -88.7% | |
| R&D / Revenue % | — | — | — | — | 47.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -24.8% | -69.7% | -14.3% | |
| Net Income | 0.0% | -16.9% | -66.6% | -17.1% | |
| EPS (Diluted) | 0.0% | -149.0% | -57.9% | -13.3% | |
| Operating Cash Flow | 0.0% | -1153.6% | 121.0% | -4446.6% | |
| Free Cash Flow | 0.0% | -1153.5% | 121.0% | -4446.7% | |
| R&D Expense | 0.0% | -38.1% | 16.1% | 30.3% | |
| SG&A Expense | 0.0% | 175.8% | 98.6% | 9.3% | |
| Total Assets | 0.0% | 11.8% | 76.7% | 19.6% | |
| Book Value / Share | 0.0% | -29.1% | 126.0% | -5.0% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | -0.8% | -20.0% | 2.4% |
Valuation
P/E (TTM)At Loss
P/S6.67
P/B1.36
10Y Low / Med / High2.16 / 28.41 / 40.05
EV/EBITDAAt Loss
EV/Revenue5.77
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.10
Cash / Share
$0.15
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| P/E Ratio | -149.80 | -60.16 | -4.63 | -5.97 | -1.07 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 6.67 | |
| P/B Ratio | 28.41 | 40.05 | 2.16 | 3.32 | 1.36 | |
| EV/EBITDA | 0.00 | -84.38 | -5.02 | -6.33 | -0.95 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 5.77 |
Analyst Estimates & Quality
Altman Z-Score
-2.36
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $47.6M | $125.9M | $177.0M |
| Net Income | -$13.9M | $19.0M | $44.7M |
| EPS | $-0.19 | $0.26 | $0.61 |
| # Analysts (EPS) | 1 | 1 | 1 |